Burkholderia mallei Hcp1 antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Burkholderia mallei Hcp1 antibodies pairs and antigen for animal health (animal Cat/Feline, Dog/Canine, Equine/Horse，Caprine/Goat, Mule, Donkey infectious disease Glanders) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Multiple species disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P253-Tg001-Ag01	Recombinant Burkholderia mallei Hcp1 protein	$3090.00
GMP-VT-P253-Tg001-Ab01	Anti-Burkholderia mallei Hcp1 mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P253-Tg001-Ab02	Anti-Burkholderia mallei Hcp1 mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P253-Tg001-Ab03	Anti-Burkholderia mallei Hcp1 human monoclonal antibody (mAb)	$3090.00
GMP-VT-P253-Tg001-Ab04	Anti-Burkholderia mallei Hcp1 human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P253-Tg001-Ag01
Product Name	Recombinant Burkholderia mallei Hcp1 protein
Pathogen	Burkholderia mallei
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Burkholderia mallei Hcp1 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Burkholderia mallei level test of animal Cat/Feline, Dog/Canine, Equine/Horse，Caprine/Goat, Mule, Donkey infectious disease with Glanders.
Tag	His
Product description	Recombinant Burkholderia mallei Hcp1 proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P253-Tg001-Ab01,GMP-VT-P253-Tg001-Ab02
Pathogen	Burkholderia mallei
Product Name	Anti-Burkholderia mallei Hcp1 mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Burkholderia mallei Hcp1 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Burkholderia mallei antibodies in Burkholderia mallei level test of animal Cat/Feline, Dog/Canine, Equine/Horse，Caprine/Goat, Mule, Donkey infectious disease with Glanders.
Product description	Anti-Burkholderia mallei Hcp1 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Burkholderia mallei antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P253-Tg001-Ab03,GMP-VT-P253-Tg001-Ab04
Pathogen	Burkholderia mallei
Product Name	Anti-Burkholderia mallei Hcp1 human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Burkholderia mallei Hcp1 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Burkholderia mallei antibodies in Burkholderia mallei level test of animal Cat/Feline, Dog/Canine, Equine/Horse，Caprine/Goat, Mule, Donkey infectious disease with Glanders.
Product description	Anti-Burkholderia mallei Hcp1 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

Burkholderia mallei is a Gram-negative bacterium that causes glanders, a highly infectious disease that primarily affects horses, but can also infect other mammals, including humans. The pathogen is transmitted through direct contact with contaminated animals or their products, such as blood, saliva, or nasal discharge. Inhalation of aerosolized droplets containing the bacteria is another route of transmission, which is of particular concern for laboratory workers, veterinarians, and other professionals who handle infected animals.

The genome of Burkholderia mallei contains two circular chromosomes, with a GC content of approximately 67%. The pathogen has a unique metabolic profile and can utilize a variety of carbon and nitrogen sources, which contributes to its pathogenicity and ability to cause persistent infections. The bacterium produces several virulence factors that promote invasion and survival in host cells, including type III and VI secretion systems, lipopolysaccharides, and capsular polysaccharides. The BimA protein is a critical virulence factor that plays a crucial role in intracellular motility and virulence.

Glanders caused by Burkholderia mallei can manifest as an acute or chronic infection with varying clinical symptoms, depending on the mode of transmission, host immune status, and bacterial load. The acute form of glanders is characterized by sudden onset of fever, respiratory distress, and septicemia, while the chronic form is typically associated with skin nodules, ulcers, and lymph node enlargement. Infection can also affect the respiratory system, causing pneumonia-like symptoms and bronchial constriction.

Diagnosis of glanders caused by Burkholderia mallei requires a combination of clinical, laboratory, and epidemiological information. Suspected cases should be reported to local health authorities, and appropriate precautions should be taken to prevent further transmission. Laboratory testing should include bacterial culture from patient samples, serology for detection of specific antibodies against the pathogen, and nucleic acid-based techniques, such as PCR assays targeting specific genes, including the tssM and fliC genes.

Treatment of glanders caused by Burkholderia mallei typically involves a combination of antimicrobial therapy, surgical intervention, and supportive care. The choice of antibiotics depends on the severity of the infection, the susceptibility of the pathogen, and the host immune status. Currently, the most effective antimicrobials for treating glanders are ceftazidime, imipenem, and meropenem, but prolonged treatment is often required to achieve a favorable outcome. In some cases, surgical debridement of infected areas or abscesses may be necessary to remove bacterial reservoirs and promote healing.

Control of glanders caused by Burkholderia mallei requires a coordinated approach that includes surveillance, diagnosis, treatment, and prevention measures. Infected animals should be promptly identified, isolated, and treated, and adequate biosecurity measures should be in place to prevent further transmission. Training and awareness programs should be implemented to educate animal handlers, veterinarians, and laboratory workers on the risks associated with glanders and how to prevent infection. Additionally, vaccination of high-risk populations, such as military personnel and veterinarians, may be considered as part of a comprehensive control strategy.

In conclusion, Burkholderia mallei is a prokaryotic pathogen that poses a serious threat to human and animal health. Effective control and prevention of glanders require a coordinated effort that includes early detection, accurate diagnosis, prompt treatment, and preventive measures, such as biosecurity and vaccination. Continued research on the biology and pathogenesis of Burkholderia mallei is essential for the development of effective therapies and vaccines to combat this emerging pathogen.

About GDU